Le Lézard
Classified in: Business
Subject: ATY

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Significant Losses to Contact Its Attorneys; Firm Investigating Possible Securities Fraud


SAN FRANCISCO, Dec. 19, 2019 /PRNewswire/ -- Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now or contact the firm immediately to learn if they qualify to recover compensable damages. The firm is investigating Allakos and investors may have valuable claims against the company and its senior management for violations of federal securities laws.

Hagens Berman Sobol Shapiro LLP

Relevant Holding Period: Before Dec. 19, 2019

Sign Upwww.hbsslaw.com/investor-fraud/ALLK

Contact An Attorney Now:

[email protected] 


844-916-0895

Allakos (ALLK) Investigation:

The investigation centers on whether Allakos and senior management misled investors about the company's clinical studies and other matters.

On Dec. 18, 2019, Seligman Investments published a scathing report entitled "A Suspect Biotech with a Phase 2 Farce, Incredulous Trial Investigators, and Warning Signs of Potential Fraud" highlighting 22 warning signs for investors.

Seligman's 215-page report concludes, in part, (1) "Allakos has a checkered history of conducting small, low-credibility trials, marked by a striking level of what we consider to be discrepancies, omissions, cherry-picking, and other red flags."

Seligman also accuses the company of having "conducted the ENIGMA phase 2 EG/EGE trial itself and served as its 'own CRO,' with at least four different trial investigators expressing concerns around the company's conduct and the trial's integrity and compliance, describing it as 'aggressive,' 'stupid,' 'dishonest,' or as something that 'won't fly with the FDA,' and their own reactions as 'shocked' and 'very bothered.'"

In addition, Seligman takes issue with "the suspicious timing of a recent option grant, which raises concerns of 1) backdating and 'spring-loading'; 2) apparent violation of rules for papers at medical conferences; and 3) questionable behavior with regard to Reg FD."

This report drove the price of Allakos shares sharply lower during the two trading days ended Dec. 19, 2019.

"We're focused on investors' losses and whether Allakos misrepresented the conditions and results of its trials," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of Allakos and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Allakos should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 844-916-0895

SOURCE Hagens Berman Sobol Shapiro LLP


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

at 00:24
In the news release, Roborock Reports 2023 Full Year Financial Results, issued 28-Mar-2024 by Roborock over PR Newswire, we are advised by the company that in the first bullet point of "Growth across Product Categories", the USD amount should read...

28 mar 2024
Royal Bank of Canada ("RBC") today announced it has completed the acquisition of HSBC Bank Canada ("HSBC Canada"). "Today marks one of the most exciting times of our 155-year history and a pivotal milestone in our long-term growth story as we...

28 mar 2024
The opening ceremony of the Boao Forum for Asia (BFA) Annual Conference 2024 was held in Boao, south China's Hainan Province on Thursday, with China's top legislator Zhao Leji stressing China's economic potential, appealing to international investors...

28 mar 2024
OKX Ventures, the investment arm of leading Web3 technology company OKX, has issued updates for March 29, 2024. OKX Ventures...

28 mar 2024
Curio Legacy Ventures (Curio), a frontrunner in nuclear technology innovation, proudly announces a strategic partnership with Navarro Research and Engineering, Inc. (Navarro). This collaboration signals a significant step forward in advancing nuclear...



News published on and distributed by: